The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus
Open accessAbstract
Background and purpose: Recommendations for using fluorodeoxyglucose positron emission tomography (FDG‐PET) to support the diagnosis of dementing neurodegenerative disorders are sparse and poorly structured. Methods: Twenty‐one questions on diagnostic issues and on semi‐automated analysis to assist visual reading were defined. Literature was reviewed to assess study design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiver operating characteristic curve, and positive/negative likelihood ratio of FDG‐PET in detecting the target conditions. Using the Delphi method, an expert panel voted for/against the use of FDG‐PET based on published evidence and expert opinion. Results: Of the 1435 papers, 58 papers provided proper quantitative assessment of test performance. The panel agreed on recommending FDG‐PET for 14 questions: diagnosing mild cognitive impairment due to Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) or dementia with Lewy bodies (DLB); diagnosing atypical AD and pseudo‐dementia; differentiating between AD and DLB, FTLD or vascular dementia, between DLB and FTLD, and between Parkinson's disease and progressive supranuclear palsy; suggesting underlying pathophysiology in corticobasal degeneration and progressive primary aphasia, and cortical dysfunction in Parkinson's disease; using semi‐automated assessment to assist visual reading. Panellists did not support FDG‐PET use for pre‐clinical stages of neurodegenerative disorders, for amyotrophic lateral sclerosis and Huntington disease diagnoses, and for amyotrophic lateral sclerosis or Huntington‐disease‐related cognitive decline. Conclusions: Despite limited formal evidence, panellists deemed FDG‐PET useful in the early and differential diagnosis of the main neurodegenerative disorders, and semi‐automated assessment helpful to assist visual reading. These decisions are proposed as interim recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“It should be considered that, according to the revised El Escorial criteria, ALS diagnosis relies on the clinical detection of motor neuron signs in multiple body segments supported by electrophysiological testing [104].”
MethodSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · cited 5×
“hypometabolism positively contributing to diagnosis, as in the case of frontotemporal lobar degeneration (FTLD) [6,7], dementia with Lewy bodies (DLB) [8]”
BackgroundInfluentialSelf-citationAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“rent NIA-AA and IWG criteria [21], but less consistent with the diagnostic criteria of other disorders for which the prodromal stage is not yet defined (as for example FTLD).”
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., Mclaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobáGyi, T., et al. (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2016.1267768 · Cited by 909
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 1×
“97 AUC range [65,70], 98% PPV, 74% NPV, 29.”
Self-citationStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Self-citationComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · cited 2×
“97 AUC range [65,70], 98% PPV, 74% NPV, 29.”
BackgroundYoung, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249
Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies
Higuchi, M., Tashiro, M., Arai, H., Okamura, N., Hara, S., Higuchi, S., Itoh, M., Shin, R.-W., Trojanowski, J. Q., & Sasaki, H. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7342 · Cited by 206
18F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias
O’Brien, J. T., Firbank, M. J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., Olsen, K., Herholz, K., Williams, D., & Lloyd, J. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.143347 · Cited by 192
Dementia with Lewy bodies: Basis of cingulate island sign
Graff-Radford, J., Murray, M. E., Lowe, V. J., Boeve, B. F., Ferman, T. J., Przybelski, S. A., Lesnick, T. G., Senjem, M. L., Gunter, J. L., Smith, G. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000734 · Cited by 163
Kerrouche, N., Herholz, K., Mielke, R., Holthoff, V., & Baron, J.-C. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600296 · Cited by 120
A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives
On behalf of the European Association of Nuclear Medicine, Morbelli, S., Garibotto, V., Van De Giessen, E., Arbizu, J., Chételat, G., Drezgza, A., Hesse, S., Lammertsma, A. A., Law, I., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3098-2 · Cited by 61 · cited 1×
“of FDG-PET performance in detecting AD in MCI patients [11], reflecting the heterogeneity of MCI criteria between studies and the inadequate follow-up period of many studies [12].”
BackgroundSelf-citationLouwersheimer, E., Keulen, M. A., Steenwijk, M. D., Wattjes, M. P., Jiskoot, L. C., Vrenken, H., Teunissen, C. E., van Berckel, B. N. M., van der Flier, W. M., Scheltens, P., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150812 · Cited by 46
Cited by
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Self-citationEANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
Guedj, E., Varrone, A., Boellaard, R., Albert, N. L., Barthel, H., van Berckel, B., Brendel, M., Cecchin, D., Ekmekcioglu, O., Garibotto, V., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05603-w · Cited by 300
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
Levin, F., Ferreira, D., Lange, C., Dyrba, M., Westman, E., Buchert, R., Teipel, S. J., Grothe, M. J., & Initiative, F. T. A. D. N. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00785-9 · Cited by 109
Boccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13355 · Cited by 82
Rebelos, E., Rinne, J. O., Nuutila, P., & Ekblad, L. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071532 · Cited by 66
Metadata
- Authors
- Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z., Boccardi, M., & the EANM‐EAN Task Force for the Prescription of FDG‐PET for Dementing Neurodegenerative Disorders
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2018-07-20
- Volume
- 25
- Issue
- 10
- Pages
- 1201-1217
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2809516213
- Cited by
- 211
- References
- 26
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.